Serum Institute of Life Sciences to double investment in Biocon unit to Rs 2457 crore
Under new terms of the alliance, it would pump in USD 150 million after converting a loan to Biocon Pharma Ltd into equity in Biocon Biologics Ltd, the company said.
New Delhi: The Serum Institute of Life Sciences will double its investment in one of Biocon Ltd 's units, giving it access to 100 million doses of vaccines annually along with the distribution rights to Serum's vaccine portfolio, the Indian biopharma firm said on Tuesday.
Serum Institute of Life Sciences is a unit of Serum Institute of India, the world's biggest vaccine maker.
Under new terms of the alliance, it would pump in $150 million after converting a loan to Biocon Pharma Ltd into equity in Biocon Biologics Ltd, the company said.
The investment is in addition to the $150 million that Serum Institute of Life Sciences invested in Biocon Biologics in November, the company said.
Biocon had signed an agreement in September 2021 to offer about 15 per cent stake in Biocon Biologics to Serum Institute of Life Sciences.
Read also: Serum Institute has produced five to six million Covovax doses: Adar Poonawalla
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd